<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923194</url>
  </required_header>
  <id_info>
    <org_study_id>000055</org_study_id>
    <nct_id>NCT01923194</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females</brief_title>
  <acronym>Compass</acronym>
  <official_title>A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction Using a Low-dose, Step-up Protocol in Chinese Females With WHO Group II Anovulatory Infertility Failing to Conceive on Clomiphene Citrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to&#xD;
      Recombinant Human Follitropin Alfa for Injection for Ovulation Induction in Chinese females&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ovulation rate defined as the percentage of subjects who present ovulation</measure>
    <time_frame>From 6 days up to 7 weeks post hCG (human chorionic gonadotropin) administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The positive serum progesterone rate</measure>
    <time_frame>6~9 days post hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The positive serum β-hCG/hCG rate</measure>
    <time_frame>18~22 days post hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical pregnancy rate</measure>
    <time_frame>6~7 weeks post hCG administration</time_frame>
    <description>Regardless of fetal heart beat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical pregnancy rate</measure>
    <time_frame>6~7 weeks post hCG administration</time_frame>
    <description>With fetal heart beat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ongoing pregnancy rate</measure>
    <time_frame>11~12 weeks post hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The follicular development</measure>
    <time_frame>On the day of hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>On the day of hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total FSH (Follicle-stimulating hormone) dose administered</measure>
    <time_frame>On the day of hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of FSH treatment days</measure>
    <time_frame>On the day of hCG administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Expected maximum of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of injection site reactions</measure>
    <time_frame>Day 1 up to Day 28 of the ovarian stimulation period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum estradiol (E2) levels</measure>
    <time_frame>On the day of hCG administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Anovulation</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Highly Purified Urofollitropin</intervention_name>
    <description>for Injection</description>
    <arm_group_label>Test Group</arm_group_label>
    <other_name>Bravelle®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human Follitropin Alfa</intervention_name>
    <description>for Injection</description>
    <arm_group_label>Comparator Group</arm_group_label>
    <other_name>Gonal-F®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form prior to screening evaluations&#xD;
&#xD;
          -  Chinese females between the ages of 20-39 years&#xD;
&#xD;
          -  Infertility for at least 1 year before screening&#xD;
&#xD;
          -  Women WHO type II anovulatory infertility with chronic anovulation (defined as&#xD;
             amenorrhoea (i.e., no menstrual bleeding for 6 months or more) or oligoamenorrhoea&#xD;
             (i.e., cycles of more than 35 days) ) with progestogen induced withdrawal bleeding or&#xD;
             spontaneous menstrual bleeding&#xD;
&#xD;
          -  Failure to conceive after at least one cycle of ovulation induction with clomiphene&#xD;
             citrate&#xD;
&#xD;
          -  Bilateral tubal patency documented by a hysterosalpingography or sonohysterography or&#xD;
             laparoscopy within 2 years prior to screening&#xD;
&#xD;
          -  Normal pelvis documented by a transvaginal ultrasound with respect to uterus,&#xD;
             Fallopian tubes and ovaries within 3 months prior to screening&#xD;
&#xD;
          -  Early follicular phase serum levels of FSH within normal limits (1-12 IU/L,) (results&#xD;
             obtained within 2 months prior to randomization)&#xD;
&#xD;
          -  LH (Luteinizing hormone), prolactin , E2 (estradiol), progesteron, total testosterone,&#xD;
             and TSH (thyrotropin) levels within normal limits for the clinical laboratory&#xD;
&#xD;
          -  Male partner with a semen analysis obtained within 12 months prior to randomisation&#xD;
             and showing acceptable values for semen according to the local laboratory, or showing&#xD;
             more than 2.000.000 progressive motile sperm per mL after capacitation (in case of IUI&#xD;
             (intrauterine insemination))&#xD;
&#xD;
          -  BMI (Body mass index) is ≥ 18.5 and &lt; 30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known clinically significant systemic disease&#xD;
&#xD;
          -  Known past or current thrombophlebitis or thromboembolism including venous thrombosis&#xD;
             disease and active or recent arterial thrombosis disease&#xD;
&#xD;
          -  Any known endocrine or metabolic abnormalities which can compromise participation in&#xD;
             the trial with the exception of controlled thyroid function disease&#xD;
&#xD;
          -  Any known concomitant medications that would interfere with evaluation of study&#xD;
             medications. Specifically, any non-study hormonal therapy (except for thyroid&#xD;
             medication), anti-psychotics, anxiolytics, hypnotics and sedatives, and need for&#xD;
             continuous use of prostaglandin inhibitors (non-steroid anti- inflammatory drugs&#xD;
             (NSAIDs), including aspirin) at the time of study entry.&#xD;
&#xD;
          -  Known history of 12 or more unsuccessful (no pregnancy achieved) ovulation induction&#xD;
             cycles&#xD;
&#xD;
          -  Any known treatment with clomiphene citrate, metformin, gonadotropins or GnRH&#xD;
             analogues within one month prior to randomisation&#xD;
&#xD;
          -  Ovarian cysts with a mean diameter ≥ 15 mm that have persisted for more than one cycle&#xD;
             or ovarian endometrioma on ultrasound&#xD;
&#xD;
          -  Known at least one previous cycle experienced luteinized unruptured follicle syndrome&#xD;
&#xD;
          -  Known abnormal results of cervical examination of clinical significance obtained&#xD;
             within 1 years prior to screening&#xD;
&#xD;
          -  Abnormal vaginal bleeding of undetermined origin&#xD;
&#xD;
          -  Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus&#xD;
&#xD;
          -  Known malformations of the sexual organs incompatible with pregnancy&#xD;
&#xD;
          -  Known current or past (last 12 months) abuse of alcohol or drugs&#xD;
&#xD;
          -  Known history of chemotherapy (except for gestational conditions) or radiotherapy&#xD;
&#xD;
          -  Finding of any clinically relevant abnormal laboratory value&#xD;
&#xD;
          -  Use of any non registered investigational drugs during 3 months before screening or&#xD;
             previous participation in the study&#xD;
&#xD;
          -  Pregnancy, lactation or contraindication to pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Tongji Medical College of HUST Tongji Medical College Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ShengJing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 12, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2013</study_first_posted>
  <last_update_submitted>August 20, 2015</last_update_submitted>
  <last_update_submitted_qc>August 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anovulation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

